J&J's Zytiga put on fast track for broader use; AZ superbug antibiotic wins clearance in EU;

 @FiercePharma: Primary-care sales reps may have a tough time seeing their docs, but cancer reps? Talk to the hand--PharmaTimes. Report | Follow @FiercePharma

> Johnson & Johnson's ($JNJ) prostate cancer drug Zytiga won fast-track review for a new use in patients who haven't been treated with chemotherapy yet. Report

> AstraZeneca's ($AZN) superbug-fighter Zinforo won approval from European regulators; it's marketed in the U.S. by Forest Laboratories under the brand name Teflaro. Report

> Johnson & Johnson's pain drug Nucynta won FDA approval for a new use in diabetic peripheral neuropathy, becoming the first opioid for that indication. Release

> Denmark's Lundbeck said its blood cancer drug Treanda won approval for marketing in Canada. Report

> Strides Arcolab subsidiary Onco Therapies won FDA approval for its version of GlaxoSmithKline's ($GSK) cancer treatment Hycamtin. Report

> Russia's top drugmaker, Pharmstandard, saw earnings drop by 27% to about $96 million for the first half of the year, as revenues dropped 13.3%. Report

> Troubled Russian pharmacy chain 36.6 reported bigger losses on discounts, as its drug subsidiary Veropharm suffered from higher taxes on flat sales. Report

> New cancer treatments accounted for 115 of Australia's 795 new drug approvals over the past decade. Report

Medical Device News

 @FierceMedDev: Evidence is building that MRI scans can be safe for people with pacemakers or implanted defibrillators--via Reuters. Article | Follow @FierceMedDev

 @MarkHFierce: TAVI works well for some patients, a new study concludes--a boost for tech made by Edwards, Medtronic and others. Report | Follow @MarkHFierce

 @DamianFierce: OmniGuide pulled in $35M from OrbiMed to market its laser surgery devices. More | Follow @DamianFierce

> Japan may be key to further propelling Resolute stent sales. Article

> St. Jude says its hypertension tech beats Medtronic, Covidien. Story

Biotech News

 @FierceBiotech: Tech startup waltzes with wireless giant in Africa to expand mobile anti-drug counterfeiting system. Article | Follow @FierceBiotech

 @JohnCFierce: ArQule tanks after tox fears force a delay in Asian lung cancer study. News | Follow @JohnCFierce

 @RyanMFierce: Achillion M&A talk again post BMS setback with Hep C nuc, but I'm thinking after BMS' M&A debacle pharma won't be so trigger-happy with deals. More | Follow @RyanMFierce

> Hot M&A trend in biopharma spurs surge in insider trading cases. Story

> Strike three: Bad data bury Eli Lilly's late-stage schizophrenia drug. Article

> Boom times for the regulatory affairs profession. Item

> Big Pharma betting billions in high-stakes hunt for the next Lipitor. Report

Biomarkers News

> Genentech and academics spot colon cancer gene markers. More

> For glioma, it's all in the letters. Story

Drug Delivery News

> Proteonomix licenses out cells that deliver anti-cancer factors. More

> Silence is golden: U.K. RNAi player signs delivery pact with MiReven. Article

> Cisplatin liposomes cut side effects. Item

And Finally... Infants given antibiotics were more likely to be overweight as youngsters, a study found. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.